Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Replicel Life Sciences Inc (TSV: RP ) N/A UNCHANGED Last Price Updated: 3:56 PM EDT, Mar 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 0.0400 (70) Ask (Size) 0.1500 (620) Prev. Close 0.0550 Today's Range N/A - N/A 52wk Range 0.0500 - 0.1300 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News RealPage Announces Strategic Partnership with Habitat for Humanity International to Build Housing in Local Communities December 14, 2023 From RealPage, Inc. Via Business Wire RealPage Accelerates the Pace of Innovation for Multifamily with Market-Leading AI-Enabled Front Office Suite November 15, 2023 From RealPage, Inc. Via Business Wire Performance More News Read More RealPage Unveils New Multifamily Rental Trends August 08, 2023 From RealPage Via Business Wire RepliCel Provides Corporate Update November 28, 2022 Via ACCESSWIRE RepliCel Announces Material Patent Milestones in Key Markets August 04, 2022 Via ACCESSWIRE RealPage Awarded 2023 ENERGY STAR Partner of the Year for Sustained Excellence March 28, 2023 From RealPage Via Business Wire Key Cannabis Exec Changes You Need To Know About: Curaleaf Names Director Of Social Equity & More Industry Appointments December 09, 2022 Via Benzinga Grabbing Opportunity In Texas Migration Numbers, Rental Fund Buys Dallas-Area Single-Family Home Development August 18, 2022 Via Benzinga DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections August 02, 2022 Via ACCESSWIRE RepliCel’s Manufacturing Inspected by Japan’s PMDA July 28, 2022 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel’s Manufacturing Inspected by Japan’s PMDA July 28, 2022 Via ACCESSWIRE CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing July 26, 2022 Via ACCESSWIRE CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing July 26, 2022 From RepliCel Life Sciences, Inc. Via AccessWire Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing July 26, 2022 Via ACCESSWIRE Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing July 26, 2022 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces Material Patent Milestones January 10, 2022 From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property RepliCel Closed Final Tranche of Strategic Investment Commitment December 21, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Terminates License Agreement with Shiseido December 21, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RealPage Agrees to Acquire HomeWiseDocs, The Premier Provider of Disclosure Management Services to the Community Association Industry December 07, 2021 From RealPage, Inc. Via Business Wire RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing November 11, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team November 09, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line October 28, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces Dermal Injector Update October 27, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy October 18, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor October 12, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Topics Economy Exposures Economy Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.